Log In
Print
BCIQ
Print
Print this Print this
 

Oxycodone/naltrexone (ALO-02)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionExtended-release oxycodone, an opioid agonist, surrounding sequestered naltrexone, an opioid receptor antagonist, designed to reduce abuse via the oral, intranasal and IV routes when crushed
Molecular Target Mu opioid receptor (MOR) (OPRM1)
Mechanism of ActionMu opioid receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard IndicationPain
Indication DetailsManage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Treat moderate to severe chronic low back pain; Treat moderate to severe chronic, non-cancer pain
Regulatory Designation

U.S. - Standard Review (Manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today